Prospective, Phase II , non-randomised interventional case series of the safety and efficacy of the use of intra-vitreal bevacizumab ("Avastin") in the treatment of macular oedema secondary to diabetic retinopathy and uveitis, and for choroidal neovascular membranes secondary to uveitis, with respect to visual acuity and central macular thickness

Trial Profile

Prospective, Phase II , non-randomised interventional case series of the safety and efficacy of the use of intra-vitreal bevacizumab ("Avastin") in the treatment of macular oedema secondary to diabetic retinopathy and uveitis, and for choroidal neovascular membranes secondary to uveitis, with respect to visual acuity and central macular thickness

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Jun 2016

At a glance

  • Drugs Bevacizumab (Primary)
  • Indications Choroidal neovascularisation; Diabetic macular oedema; Retinal oedema
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Oct 2009 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top